Trial Profile
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary) ; Tretinoin (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 05 Sep 2023 New trial record